Affymax (AFFY +10.9%) shares resume trading, popping more than 10% after the company confirms...

|By:, SA News Editor

Affymax (AFFY +10.9%) shares resume trading, popping more than 10% after the company confirms the FDA cleared the company's peginesatide anemia treatment for patients on dialysis for chronic kidney disease. The drug will be AFFY's first marketed product. Competitor Amgen (AMGN +0.5%) also trades higher.